Systematic review finds anthocyanin reduces IL-8 and IFN-γ, implying benefits in inflammation management.
Previous research has demonstrated the anti‐inflammatory effects of anthocyanin supplementation, as evidenced by reduced levels of inflammatory adipokines in obese populations. However, the relationship between anthocyanin intake and obesity‐related adipokines remains unclear in existing research. To investigate this, we hypothesised that anthocyanin supplementation would significantly reduce plasma concentrations of interleukin‐8 (IL‐8), IL‐18, interferon‐gamma (IFN‐γ) and resistin, and significantly increase plasma concentrations of IL‐10 in a healthy, overweight, and obese population. A systematic search of PubMed and Scopus was conducted between September 2024 and November 2024, resulting in 22 eligible studies for inclusion. The standardised mean difference was used to establish the effect size, and I‐squared was used to determine heterogeneity. The risk of bias was assessed using Cochrane's risk of bias assessment tool. An Egger's test and funnel plot were utilised to determine any publication bias. The meta‐analysis data showed that the inclusion of anthocyanins resulted in significant reductions in IL‐8 ( p = 0.004) and IFN‐γ ( p = 0.02). However, we observed that IL‐10 ( p = 0.97), IL‐18 ( p = 0.28) and resistin ( p = 0.42) did not show a significant effect after anthocyanin consumption. The findings indicate that anthocyanin supplementation can significantly decrease circulating plasma levels of IL‐8 and IFN‐γ in healthy, overweight, and obese populations, but not IL‐10, IL‐18 or resistin levels. Trial Registration: PROSPERO: CRD420251037683 ( https://www.crd.york.ac.uk/PROSPERO/view/CRD420251037683 ).
No takes yet. Share an insight, caveat, or question.
Young et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: